IDT Corp 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by IDT Corporation on June 9, 2026. The filing addresses corporate governance changes, specifically the resignation of a director and the appointment of a new director to the Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Resignation: Irwin Katsof resigned from the Board of Directors and all associated committees on June 9, 2026. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
- Director Appointment: William Conkling was appointed to the Board on June 9, 2026. His term expires at the 2026 annual meeting of stockholders.
Outlook, Commentary, and Risks
Management Commentary: The Board determined that Mr. Conkling is "independent" under NYSE listing standards and SEC rules. He is expected to serve as the Chairman of the Audit Committee, the Audit Committee Financial Expert, and as a member of the Compensation and Corporate Governance Committees.
Biographical Context: Mr. Conkling, age 55, brings significant commercial experience, having served as Chief Commercial Officer of Protara Therapeutics Inc. since June 2025 and previously as CEO of Rafael Holdings, Inc. He also has over 10 years of experience at Novartis and led commercialization efforts at Immunomedics Inc.
Compensation: Mr. Conkling is eligible to participate in the Company's Non-Employee Director Compensation Program, which includes cash and equity-based awards.
Key Facts for Investor Verification
- Confirm the effective date of Irwin Katsof's resignation and the status of any pending committee assignments.
- Verify William Conkling's independence status and his specific committee assignments (Audit, Compensation, Corporate Governance).
- Review the terms of the Non-Employee Director Compensation Program applicable to Mr. Conkling.
- Check for any subsequent filings regarding the 2026 annual meeting of stockholders where Mr. Conkling's term will expire.